ERYTECH Pharma S.A. (ERYP) surged in the pre-market after announcing a new patent for treating rare metabolic diseases and information on voting rights. ERYP values at $2.01, gaining more than 6.35% compared to yesterday’s closing price. The stock closed at $1.86 at the end of the last trading session. The stock volume was approximately 45.75K shares at the end of the previous trading session.
ERYTECH Pharma S.A. (ERYP) increased its patent portfolio
ERYTECH Pharma S.A. (ERYP) announced in a press release that Arginase-1 deficiency (A1D), an uncommon metabolic illness, was granted a U.S. patent. It also covers Oncology, septic shock, and angiogenesis.
These therapies will help lower abnormal levels of different metabolites, which can occur in some inborn errors of metabolism illnesses. However, hypersensitivity and rapid clearance sometimes overshadow therapeutic benefits. So there’s a big desire for a more bearable ERT.
Monthly information on voting rights
ERYP announced the monthly report along with an increased patent portfolio. As of January 31, 2022, the total shares composing the share capital are 31,018,553. The total of brut voting rights is 32,518,339. The total of net voting rights is 32,515,839. The numbers are unchanged compared to the end of December 31, 2021.
The CEO of ERYP remarks on the new patent
ERYTECH’s CEO, Gil Beyen, said the company is happy to broaden its patent coverage for its red blood cell technology in rare diseases. In addition to oncology and cancer metabolism, their rare disease patents bolster their technology’s clinical application potential. With positive preclinical evidence in Arginase Deficiency (A1D), the company’s patent estate protects current and future developments and collaborations in this domain.
Conclusion
About 310 issued and 45 pending patents encompass 16 patent families owned by ERYTECH, a global patent portfolio. The company looks forward to using the recent development technology to cure other related diseases. The company is keen on increasing the revenue with the new patents joining the company’s revenue stream.
